Liver transplantation and hepatitis B virus infection: The situation seems to be under control, but the virus is still there

Journal of Hepatology

Volumn 34, Issue 6, 2001, Pages 943-945

  Samuel, Didier ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B ANTIBODY; LAMIVUDINE;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG COST; DRUG TOLERABILITY; EDITORIAL; HEPATITIS B; HUMAN; INFECTION CONTROL; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REINFECTION;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS;

EID: 0034952782     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00102-7     Document Type: Editorial

References (23)

1. Liver transplantation in European patients with the hepatitis B surfaces antigen
2. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: A concise review
3. Mercury poisoning associated with high dose hepatitis B immune globulin administration after liver transplantation for chronic hepatitis B
4. Eurohep consensus report on the management of liver transplantation for hepatitis B virus infection
5. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
6. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
7. Prophylaxis against hepatitis B recurrence following liver transplantation using combination of lamivudine and hepatitis B immune globulin
8. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
9. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
10. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
11. High pre-treatment serum hepatitis B virus titer predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation
12. Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients
13. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B
14. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin
15. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation
16. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin
17. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis
18. Lamivudine and low-dose hepatitis immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation -possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection
19. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation
20. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus
21. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
22. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation
23. Residual HBV DNA at 10 years post-transplantation in patients receiving long-term anti-HBS immunoglobulins